DelveInsight’s ‘Wet AMD Pipeline Insight 2022’ report provides comprehensive global coverage of available, marketed, and pipeline Wet AMD therapies in various stages of clinical development, major pharmaceutical players working to advance the pipeline space and future growth potential of the Wet AMD pipeline domain.
Key Takeaways from the Wet AMD Pipeline Report
Request a sample and discover the recent advances in Wet AMD treatment drugs @Wet AMD Pipeline Report
The Wet AMD pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Wet AMD products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Wet AMD pipeline landscape.
Wet AMD Overview
Wet AMD, also known as neovascular AMD or exudative AMD, is a type of retinal degeneration characterized by abnormal choroidal neovascularization beneath the retina and macula lutea. Wet AMD is less common but more severe than dry AMD. The wet/neovascular type affects 10-15% of people with age-related macular degeneration but accounts for 90% of all cases of severe vision loss caused by the disease. It is responsible for 90% of severe vision loss in people with AMD. Everyone who gets wet AMD used to have dry AMD.
Central visual blurring and distortion are the most common Wet AMD symptoms. The majority of patients complain that straight lines look crooked or wavy. Color photographs, fluorescein angiography, and optical coherence tomography can help confirm the Wet AMD diagnosis and guide Wet AMD treatment.
Find out more about the disease and recent developments in Wet AMD drugs @Wet AMD Treatment Drugs
Wet AMD Pipeline Drugs
Drug
Company
Phase
MoA
RoA
LY09004
Luye Pharma
Phase III
Vascular endothelial growth factor A inhibitor
Intraocular
KSI-301
Kodiak Sciences
Vascular endothelial growth factors inhibitor
Intravitreal
GEM-103
Gemini Therapeutics
Phase II
Complement factor H replacement
Zimura
Iveric Bio
Complement C5 inhibitor
RC 28 E
RemeGen
Phase I/II
BI 836880
Boehringer Ingelheim
AAVCAGsCD59
Janssen Research and Development
Phase I
Complement system protein inhibitor
Learn more about the emerging Wet AMD pipeline therapies @Wet AMD Clinical Trials
Wet AMD Therapeutics Assessment
The Wet AMD pipeline report proffers an integral view of the Wet AMD emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Wet AMD Pipeline Report
Dive deep into rich insights for drugs for Wet AMD treatment, visit @Wet AMD Treatment
Table of Contents
1.
Wet AMD Pipeline Report Introduction
2.
Wet AMD Pipeline Report Executive Summary
3.
Wet AMD Pipeline: Overview
4.
Analytical Perspective In-depth Commercial Assessment
5.
Wet AMD Pipeline Therapeutics
6.
Wet AMD Pipeline: Late Stage Products (Pre-registration)
7.
Wet AMD Pipeline: Late Stage Products (Phase III)
8.
Wet AMD Pipeline: Mid Stage Products (Phase II)
9.
Wet AMD Pipeline: Early Stage Products (Phase I)
10.
Wet AMD Pipeline Therapeutics Assessment
11.
Inactive Products in the Wet AMD Pipeline
12.
Company-University Collaborations (Licensing/Partnering) Analysis
13.
Key Companies
14.
Key Products in the Wet AMD Pipeline
15.
Unmet Needs
16.
Market Drivers and Barriers
17.
Future Perspectives and Conclusion
18.
Analyst Views
19.
Appendix
For further information on Wet AMD pipeline therapeutics, reach out @Wet AMD Drugs
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-pipeline-insight